FindTrial
Sign In

IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide

IL-22-producing CD4+T cells in Rheumatic Diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-16009278
Enrollment
Unknown
Registered
2016-09-27
Start date
2011-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

healthy individuals:null
RA patients:null

Sponsors

the First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 79 Years

Inclusion criteria

Inclusion criteria: New onset RA patients

Exclusion criteria

Exclusion criteria: Patients with any of the following conditions were excluded: recent infection, a history of other autoimmune diseases such as myositis or systemic sclerosis, or a history of treatment with immunosuppressive agents or glucocorticoids within the past six months

Design outcomes

Primary

MeasureTime frame
IL-22+ T cells;IL-22;IL-17;IFN-?;—

Countries

China

Contacts

Public ContactZhenyu Jiang

the First Hospital of Jilin University

jiangzhenyu2012@163.com+86 15843079623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026